A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer

PD1 inhibition is effective in patients with metastatic urothelial cancer (mUC), yet a large fraction of patients does not respond. In this study, we aimed to identify a blood-based immune marker associated with non-response to facilitate patient selection for anti-PD1. To this end, we quantified 18...

Descripción completa

Detalles Bibliográficos
Autores principales: Rijnders, Maud, Robbrecht, Debbie G. J., Oostvogels, Astrid A. M., van Brakel, Mandy, Boormans, Joost L., Aarts, Maureen J. B., Balcioglu, Hayri E., Hamberg, Paul, Voortman, Jens, Westgeest, Hans M., Lolkema, Martijn P., de Wit, Ronald, van der Veldt, Astrid A. M., Debets, Reno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947015/
https://www.ncbi.nlm.nih.gov/pubmed/35976415
http://dx.doi.org/10.1007/s00262-022-03250-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947015/
https://www.ncbi.nlm.nih.gov/pubmed/35976415
http://dx.doi.org/10.1007/s00262-022-03250-0

Ejemplares similares